离子液体增强多功能水凝用于治疗肠皮
Jinjoo Kim1, Hyeongseop Keum1, Hassan Albadawi1
1The Laboratory for Patient-Inspired Engineering, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ, 85259, USA.
Advanced materials (Deerfield Beach, Fla.)
|May 12, 2025
概括
一种新的可注射水凝,ECFGel,通过粘附于组织,杀死细菌并促进愈合,有效地治疗皮内囊. 这种创新疗法显示出在复杂瘤病例中改善患者结果的巨大潜力.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 手术创新 在外科创新.
背景情况:
- 肠皮囊 (ECF) 带来了重大的临床挑战,由于有效治疗方法有限,导致高发病率和死亡率.
- 目前对ECF的治疗选择往往缺乏有效性,并且可能具有侵入性,需要新的闭塞和愈合方法.
研究的目的:
- 开发和评估ECFGel,这是一种多功能,可注射的水凝,旨在封闭,绝育和治愈皮内囊管道.
- 在临床前模型中评估ECFGel的物理化学性质,抗菌疗效和体内性能.
主要方法:
- 使用凝和氧化德克斯 (O-Dex) 进行组织粘附,使用离子液体 (IL) 进行抗微生物和机械增强,并使用 (IOH) 进行放射性增强.
- 在猪组织中评估了水凝的凝,机械性能,抗胀行为,生物降解性和通道封闭性.
- 评估了对临床病原体的抗微生物活性和猪周围囊模型中的有效性,测量了愈合,细菌负载和组织再生标记.
主要成果:
- 在猪模型中,ECFGel表现出快速凝,增强机械强度和有效的通道封闭.
- 水凝对抗耐药性病原体表现出强大的抗微生物活性,并在猪状模型中促进了完全治愈.
- 与对照组相比,ECFGel治疗导致改善组织成熟,减少细菌负担,增加细胞增殖和血管化.
结论:
- ECFGel是一种有前途的多功能生物材料,用于治疗受感染的皮内.
- 可注射水凝的独特特性有助于阻塞,绝育和加速组织再生.
- ECFGel代表了一种潜在的新型治疗策略,以改善患有ECF的患者的治疗结果.
相关概念视频
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...